药明康德两次出售药明康德股票获得超20亿元收益,被减持的药明合联盘中跌超13%。 1月13日,无锡药明康德新药开发股份有限公司(药明康德,603259.SH;2359.HK)公告称,公司通过间接控股子公司持有联营企业 WuXi XDC Cayman Inc.(药明合联生物技术有限公司,简称“药明合联”,2268.HK)的股票。2024年11月8日及2025年1月10日,通过两次大宗交易,公司累计...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.